RadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 25.0%, EPS fell 47.4%, free cash flow fell 43.2% and total debt rose 21.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow RDNT
RadNet, Inc. (RDNT) P/E ratio
RadNet, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 4,866× (March 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 2,328× | (32.64%) |
| FY2023 | 3,456× | 3,237.34% |
| FY2022 | 104× | 61.64% |
| FY2021 | 64.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 70.0× | 354.28% |
| FY2018 | 15.4× | — |
| FY2017 | 0.0× | — |
| FY2016 | 36.9× | 1.48% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| RDNT RadNet, Inc. | n/m |
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| QGEN QIAGEN N.V. compare | 23.6× |
| CDNA CareDx, Inc. compare | 29.7× |
| VCYT Veracyte, Inc. compare | 29.9× |
| SHC Sotera Health Company compare | 31.4× |
| BLLN BillionToOne, Inc. compare | 95.0× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)